Cost-effectiveness analysis of extended thromboprophylaxis with rivaroxaban versus no prophylaxis in high-risk patients after hospitalisation for COVID-19: an economic modelling study Documento uri icon

  •  
  • Visão geral
  •  
  • Pesquisas
  •  
  • Identidade
  •  
  • Informação adicional documento
  •  
  • Outro
  •  
  • Ver todos
  •